Keyphrases
Antithymocyte Globulin
89%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
61%
Immune Reconstitution
59%
Pediatric
47%
Individualized Dosing
39%
Graft-versus-host Disease (GvHD)
39%
Cord Blood Transplantation
36%
T Cells
31%
Population Pharmacokinetics
30%
Hematopoietic Cell Transplantation
30%
Thymoglobulin
24%
Pharmacodynamics
20%
CD4+
18%
Therapeutic Drug Monitoring
18%
T Cell Reconstitution
18%
Serotherapy
17%
Dosing Regimen
17%
Hazard Ratio
16%
Alemtuzumab
15%
Survival Outcomes
15%
Haemopoietic Stem Cell Transplantation
15%
Unrelated Cord Blood Transplantation
15%
Melphalan
15%
Cohort Analysis
15%
Older Adults
15%
Improved Outcomes
13%
Conditioning Regimen
12%
Hematopoietic Stem Cell Transplantation
11%
Human Herpesvirus 6 (HHV-6)
11%
Area under the Curve
10%
Graft Failure
10%
Viral Reactivation
10%
Pharmacokinetics
10%
Improved Survival
10%
High Risk
9%
Reconstitution
9%
Overall Survival
9%
Fludarabine
8%
T Cell Survival
8%
Acute Leukemia
8%
Evidence-based
8%
Acute Lymphoblastic Leukemia
8%
Large Cohort
8%
Chimeric Antigen Receptor T-cell Therapy
7%
Globulin
7%
Parachute
7%
High Dose
7%
Conditioning Regime
7%
Cell Grafting
7%
Outcome Prediction
7%
Immunology and Microbiology
Anti-Thymocyte Globulin
100%
Immune Reconstitution
56%
T Cell
54%
Cell Transplantation
36%
Cord Blood Stem Cell Transplantation
36%
CD4
27%
Graft-Versus-Host Disease
26%
Allogeneic Hematopoietic Stem Cell Transplantation
24%
Hematopoietic Cell
21%
Conditioning
17%
Pharmacokinetics
16%
Pharmacodynamics
15%
Hematopoietic Stem Cell Transplantation
11%
Human Herpesvirus 6
11%
Overall Survival
10%
Blood Plasma
9%
Alemtuzumab
9%
Myeloid
8%
Arm
8%
Acute Graft Versus Host Disease
7%
Liquid Chromatography Tandem Mass Spectrometry
7%
Leporidae
7%
Immunosuppression
7%
Filgrastim
7%
Engraftment
7%
Thymocyte
7%
Drug Megadose
7%
Viremia
7%
Stem Cell Transplantation
7%
Systemic Scleroderma
7%
Allogeneic Stem Cell Transplantation
7%
Autologous Hematopoietic Stem Cell Transplantation
7%
Adenoviridae
7%
Event Free Survival
6%
Natural Killer Cell
6%
T-Helper Cell
5%
Cytomegalovirus
5%
Lymphocyte Count
5%
Epstein Barr Virus
5%
Umbilical Cord Blood
5%
Pharmacology, Toxicology and Pharmaceutical Science
Thymocyte Antibody
61%
Pharmacokinetics
36%
Therapeutic Drug Monitoring
19%
Alemtuzumab
17%
Melphalan
15%
Graft Versus Host Reaction
14%
Pharmacodynamics
13%
Acute Lymphoblastic Leukemia
9%
Disease
9%
Globulin
8%
Acute Leukemia
7%
Rhabdomyosarcoma
7%
Systemic Sclerosis
7%
Chimeric Antigen Receptor
7%
Pharmacotherapy
7%
Pharmacodynamic Modeling
7%
High Dose Chemotherapy
7%
Fludarabine
7%
Controlled Clinical Trial
6%
Infection
6%
Graft Failure
5%
Busulfan
5%